GSK has announced it is moving its experimental mRNA-based influenza vaccine into Phase III clinical trials, directly challenging Moderna’s lead in the mRNA vaccine space. The vaccine, which uses messenger RNA technology similar to that used in COVID-19 shots, aims to provide better protection against seasonal flu. The Phase III trial will enroll thousands of adults to evaluate safety and efficacy compared to existing flu vaccines.

Key takeaways

  • GSK’s mRNA flu vaccine has entered Phase III clinical testing, the final stage before regulatory approval.
  • The trial will compare the mRNA vaccine against standard flu shots in a large population.
  • GSK is aiming to catch up to Moderna, which already has an mRNA flu vaccine in late-stage development.
  • If successful, the vaccine could offer improved effectiveness and faster production during flu seasons.

What the Phase III trial involves

According to the original report from Clinical Trials Arena, GSK’s Phase III trial will test the mRNA flu vaccine in a large group of adults. The study is designed to measure how well the vaccine prevents laboratory-confirmed influenza compared to current standard vaccines. Researchers will also monitor for any side effects over the course of one flu season.

The trial marks a significant step for GSK, which has been investing heavily in mRNA technology after initially lagging behind in the COVID-19 vaccine race. The company hopes that its mRNA platform can deliver more potent and broadly protective flu vaccines, potentially reducing the need for annual reformulation.

GSK’s push into mRNA vaccines

GSK has been building its mRNA capabilities through partnerships and internal research. The flu vaccine candidate is one of several mRNA programs in the company’s pipeline. By moving into Phase III, GSK signals that it believes its technology can compete with established players like Moderna and Pfizer.

The company’s strategy involves targeting multiple strains of influenza with a single shot, which could simplify vaccination campaigns. Traditional flu vaccines are often only moderately effective due to strain mismatches. mRNA vaccines can be updated more quickly, which may improve season-to-season protection.

Competition with Moderna

Moderna currently has its own mRNA flu vaccine, mRNA-1010, which has already completed Phase III trials and is under regulatory review in some countries. GSK’s entry into Phase III sets up a direct rivalry. Both companies are racing to be the first to offer an mRNA alternative to traditional flu shots.

The original report notes that GSK hopes to leverage its experience with adjuvanted vaccines and large-scale manufacturing to gain an edge. However, Moderna has a head start in mRNA production and a proven track record with its COVID-19 vaccine. The outcome of these trials will determine which company can bring a superior product to market.

Potential impact on flu prevention

If GSK’s mRNA flu vaccine proves safe and effective, it could change how seasonal flu is prevented. mRNA vaccines are generally faster to manufacture and can be tailored to emerging strains more easily than egg-based or cell-based vaccines. This could lead to better annual protection and reduce the burden of flu-related hospitalizations and deaths.

The Phase III data will be closely watched by public health officials. GSK has not provided a timeline for potential approval, but successful results could lead to regulatory submissions within the next year or two.

Frequently Asked Questions

What is the GSK mRNA flu vaccine?

The GSK mRNA flu vaccine is an experimental shot that uses messenger RNA to instruct cells to produce proteins that mimic flu virus components, training the immune system to fight infection. It is designed to protect against multiple influenza strains and is now in Phase III clinical trials.

How does it differ from Moderna’s mRNA flu vaccine?

Both vaccines use similar mRNA technology, but they differ in their specific antigen designs and manufacturing processes. GSK’s candidate may include proprietary formulations or adjuvants to boost immune response. Moderna’s mRNA-1010 is further along, having completed Phase III and entered regulatory review. Direct head-to-head comparisons are not yet available.

When will the GSK mRNA flu vaccine be available?

Availability depends on the outcome of the Phase III trial and subsequent regulatory approvals. If results are positive, GSK could submit for authorization in 2025 or later. Widespread use would likely not occur until at least the 2026-2027 flu season, pending manufacturing scale-up and public health recommendations.

This is an original report by Vital Signs Today, informed by reporting from Google News. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.